logo BDSP

Base documentaire


  1. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States.

    Article - En anglais

    Objective 

    To determine the willingness of populations at high risk of HIV-1 infection to participate in HIV vaccine efficacy trials, determine factors influencing decision-making, and evaluate knowledge levels of vaccine trial concepts.

    Design 

    Cross-sectional study.

    Methods 

    HlV-1-negative homosexual men, male and female injecting drug users and non-injecting women at heterosexual risk were recruited in eight cities in the United States (n=4892).

    Results 

    A substantial proportion of the study population (77%) would definitely (27%) or probably (50%) be willing to participate in a randomized vaccine efficacy trial.

    Increased willingness was associated with high-risk behaviors, lower education level, being uninsured or covered by public insurance, and not having been in a previous vaccine preparedness study.

    Altruism and a desire for protection from the vaccine were major motivators for participation.

    Major concerns included positive HIV-1 antibody test due to vaccine, safety of the vaccine, and possible problems with insurance or foreign travel.

    Baseline knowledge of vaccine trial concepts was low.

    Conclusions 

    It is likely that high-risk volunteers will be willing to enroll in HIV vaccine efficacy trials.

    A variety of participant and community educational strategies are needed to address participant concerns, and to ensure understanding of key concepts prior to giving consent for concepts prior to giving consent for participation.

    Mots-clés Pascal : Population, Facteur risque, Critère, Expérimentation, Vaccin, Homme, SIDA, Virose, Infection, Volontaire, Etats Unis, Amérique du Nord, Amérique, Immunopathologie, Immunodéficit

    Mots-clés Pascal anglais : Population, Risk factor, Criterion, Experimentation, Vaccine, Human, AIDS, Viral disease, Infection, Volunteer, United States, North America, America, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0277202

    Code Inist : 002B05C02D. Création : 27/11/1998.